NextCure, Inc. (NASDAQ: NXTC) will present Phase 1 data for its CDH6‑targeted antibody‑drug conjugate, SIM0505, at the American Society of Clinical Oncology (ASCO) 2026 meeting in Chicago on Monday, June 1, 2026.
The data will come from an open‑label, first‑in‑human, Phase 1 study (NCT06792552) that enrolls patients with advanced solid tumors, with a particular focus on platinum‑resistant ovarian cancer. The study evaluates the safety profile and preliminary antitumor activity of SIM0505, a novel ADC that couples a CDH6‑specific antibody to a topoisomerase‑1 inhibitor payload.
This presentation marks the first public disclosure of clinical outcomes for SIM0505, a milestone that can shape investor confidence, attract potential partnership discussions, and support future capital‑raising efforts. The data will also provide a benchmark for the company’s ongoing development strategy and help position SIM0505 within the competitive ADC landscape.
In addition to the ASCO presentation, NextCure received Fast‑Track designation from the U.S. Food and Drug Administration on April 7, 2026 for SIM0505 in platinum‑resistant ovarian cancer, a regulatory step that can accelerate development and review. The company reported $41.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and a net loss of $55.8 million for the full year. Management expects these resources to fund operations and capital expenditures through the first half of 2027.
The announcement is part of a series of positive developments for NextCure, reinforcing the company’s progress in advancing its lead candidate and strengthening its position in the oncology pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.